-
公开(公告)号:US08883828B2
公开(公告)日:2014-11-11
申请号:US13669083
申请日:2012-11-05
Applicant: Array BioPharma Inc.
Inventor: Thomas Daniel Aicher , Steven Armen Boyd , Mark Joseph Chicarelli , Kevin Ronald Condroski , Ronald Jay Hinklin , Ajay Singh
IPC: A01N43/40 , C07D417/00 , C07D417/14 , C07D491/04 , C07D487/04 , C07D513/04 , C07D417/12 , C07D471/04 , C07D413/14 , C07D495/04
CPC classification number: C07D417/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/04 , C07D495/04 , C07D513/04
Abstract: Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
Abstract translation: 提供了可用于治疗和/或预防由缺乏水平的葡糖激酶活性(例如糖尿病)介导的疾病的化合物。 还提供了治疗或预防以葡萄糖激酶不足活性为特征的疾病和病症的方法,或者可以通过激活葡糖激酶治疗。
-
公开(公告)号:US11884664B2
公开(公告)日:2024-01-30
申请号:US17720070
申请日:2022-04-13
Applicant: Array BioPharma Inc.
Inventor: James Francis Blake , Mark Laurence Boys , Mark Joseph Chicarelli , Adam Wade Cook , Mohamed S. A. Elsayed , Jay Bradford Fell , John P. Fischer , Ronald Jay Hinklin , Yutong Jiang , Oren Teague McNulty , Macedonio J. Mejia , Martha E. Rodriguez , Christina Elizabeth Wong
IPC: C07D401/04 , A61K31/53 , C07D471/04 , A61P35/00 , C07D401/14 , C07D471/10 , C07D513/10 , A61K45/06
CPC classification number: C07D471/04 , A61P35/00 , C07D401/14 , C07D471/10 , C07D513/10 , A61K45/06
Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
公开(公告)号:US11780835B2
公开(公告)日:2023-10-10
申请号:US17376571
申请日:2021-07-15
Applicant: Array BioPharma Inc.
Inventor: Ronald Jay Hinklin , Shelley Allen , Patrick Barbour , Adam Cook , Joshua Dahlke , John Gaudino , Ellen Laird , Oren T. McNulty , Qian Zhao
IPC: C07D471/04
CPC classification number: C07D471/04
Abstract: Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.
-
公开(公告)号:US11247990B1
公开(公告)日:2022-02-15
申请号:US16893784
申请日:2018-12-05
Applicant: ARRAY BIOPHARMA INC.
Inventor: Shelley Allen , Mark Laurence Boys , Adam Cook , John Gaudino , Ronald Jay Hinklin , Ellen Laird , Oren T. McNulty , Andrew T. Metcalf , Brad Newhouse , John E. Robinson
IPC: C07D471/04 , C07D519/00
Abstract: Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein Ring A, X1, X2, X3, R1, R2 and R3 are as defined herein, which are inhibitors of one or more TAM kinases and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor.
-
公开(公告)号:US20200291039A1
公开(公告)日:2020-09-17
申请号:US16890663
申请日:2020-06-02
Applicant: Array BioPharma Inc. , Celgene Corporation
Inventor: Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett
IPC: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K45/06
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
-
公开(公告)号:US10730880B2
公开(公告)日:2020-08-04
申请号:US16212493
申请日:2018-12-06
Applicant: Array BioPharma Inc. , Celgene Corporation
Inventor: Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett
IPC: A61K45/06 , C07D487/04 , A61K31/4985 , A61K31/5377
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
-
公开(公告)号:US20200079770A1
公开(公告)日:2020-03-12
申请号:US16555432
申请日:2019-08-29
Applicant: Array BioPharma Inc.
Inventor: Ronald Jay Hinklin , Shelley Allen , Patrick Barbour , Adam Cook , Joshua Dahlke , John Gaudino , Ellen Laird , Oren T. McNulty , Qian Zhao
IPC: C07D471/04
Abstract: Provided herein are compounds of the Formula I: and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.
-
公开(公告)号:US10125134B2
公开(公告)日:2018-11-13
申请号:US15814279
申请日:2017-11-15
Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.
Inventor: James F. Blake , Laurence E. Burgess , Mark Joseph Chicarelli , James Gail Christensen , Jay Bradford Fell , John P. Fischer , John J. Gaudino , Erik James Hicken , Ronald Jay Hinklin , Matthew Randolf Lee , Matthew Arnold Marx , Macedonio J. Mejia , Martha E. Rodriguez , Pavel Savechenkov , Tony P. Tang , Guy P. A. Vigers , Henry J. Zecca
IPC: C07D471/04 , C07D519/00 , A61K31/519
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
公开(公告)号:US20230011441A1
公开(公告)日:2023-01-12
申请号:US17376571
申请日:2021-07-15
Applicant: Array BioPharma Inc.
Inventor: Ronald Jay Hinklin , Shelley Allen , Patrick Barbour , Adam Cook , Joshua Dahlke , John Gaudino , Ellen Laird , Oren T. McNulty , Qian Zhao
IPC: C07D471/04
Abstract: Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.
-
公开(公告)号:US11267812B2
公开(公告)日:2022-03-08
申请号:US16099398
申请日:2017-05-17
Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.
Inventor: John P. Fischer , Jay Bradford Fell , James F. Blake , Ronald Jay Hinklin , Macedonio J. Mejia , Erik James Hicken , Mark Joseph Chicarelli , John J. Gaudino , Guy P. A. Vigers , Laurence E. Burgess , Matthew Arnold Marx , James Gail Christensen , Matthew Randolph Lee , Pavel Savechenkov , Henry J. Zecca , Tony P. Tang
IPC: C07D471/04 , C07D519/00 , A61P35/00
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
-
-
-
-
-
-
-
-